[
    [
        {
            "time": "2021-02-09",
            "original_text": "Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19",
            "features": {
                "keywords": [
                    "Emergency Use Authorization",
                    "Lilly",
                    "bamlanivimab",
                    "etesevimab",
                    "post-exposure",
                    "prophylaxis",
                    "COVID-19"
                ],
                "sentiment_score": 0.75,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-02-09",
            "original_text": "UPDATE 1-FDA revises Lilly's COVID-19 antibody combo EUA for use after exposure to virus",
            "features": {
                "keywords": [
                    "FDA",
                    "revises",
                    "Lilly",
                    "COVID-19",
                    "antibody",
                    "combo",
                    "EUA",
                    "exposure",
                    "virus"
                ],
                "sentiment_score": 0.65,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "UPDATE 1-FDA revises Lilly's COVID-19 antibody combo EUA for use after exposure to virus",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "2021-02-09",
            "original_text": "FDA revises Lilly's COVID-19 antibody combo EUA for use after exposure to virus",
            "features": {
                "keywords": [
                    "FDA",
                    "revises",
                    "Lilly",
                    "COVID-19",
                    "antibody",
                    "combo",
                    "EUA",
                    "exposure",
                    "virus"
                ],
                "sentiment_score": 0.65,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "FDA revises Lilly's COVID-19 antibody combo EUA for use after exposure to virus",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-02-09",
            "original_text": "Regeneron, Lilly Get New COVID Drug Deals From Government",
            "features": {
                "keywords": [
                    "Regeneron",
                    "Lilly",
                    "New",
                    "COVID",
                    "Drug",
                    "Deals",
                    "Government"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Regeneron, Lilly Get New COVID Drug Deals From Government",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]